Have you been diagnosed with triple negative breast cancer and have residual disease after receiving preoperative therapy and surgery?

Do you have stage III colon cancer? Have you already completed surgery? If so, you may qualify for a study that uses a blood test called ctDNA to determine your treatment and to monitor for recurrence.

Do you have metastatic renal cell carcinoma? If so, you may be able to take part in a research study collecting information about how your therapy is affecting your quality of life.

Have you been diagnosed with urothelial carcinoma? If so, you may be able to take part in a research study evaluation of an investigational treatment called FX-909 in cancer patients.

The purpose of this study is to measure the efficacy and safety of durvalumab IV solution plus bevacizumab IV solution after transarterial radioembolization(Y90 glass microsphere TARE) in participants with unresectable HCC amenable to locoregional therapy.

Do you have advanced or metastatic non small cell lung cancer, squamous cell carcinoma of the head and neck, colorectal cancer, or renal cell carcionma? Have you tried previous therapies that did not work? If so, you may be able to take part in this study. Investigational study drug is provided.

This study aims to find better ways to serve children with autism spectrum disorder (ASD). We will use 3 rounds of online surveys to develop a list of functionality features that are most relevant for serving school-age autistic children. We hope this list can be used to improve services and support for those who are on the autism spectrum.

Are you between the ages of 40 and 75? Are you willing to give a one-time blood sample? If so, you may be able to take part in a research study that is being used to develop and validate blood tests for early cancer detection.

Do you have triple negative breast cancer? Have you had surgery following chemotherapy? You may be able to participate in a study to find out if stopping pembrolizumab infusions after surgery is just as effective at reducing your risk of cancer recurrence.

Are you over 60 and were recently diagnosed with mantle cell lymphoma? You may be able to participate in a research study to determine whether patients who reach complete disease remission after treatment with rituximab and zanubrutinib, will remain longer in remission with or without continuous zanubrutinib treatment.